ATRA Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of 10.24%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Atara Biotherapeutics, Inc. has a consensus price target of $16.33, signalling upside risk potential of 15.02%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.90 which suggests that it could grow by 59.8%. Given that Amicus Therapeutics, Inc. has higher upside potential than Atara Biotherapeutics, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.416, which suggesting that the stock is 141.609% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 6.48x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.11x versus 5.09x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of -255.85%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Atara Biotherapeutics, Inc. has a consensus price target of $16.33, signalling upside risk potential of 15.02%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Atara Biotherapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Atara Biotherapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.416, which suggesting that the stock is 141.609% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 6.48x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.11x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacira Biosciences, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of 3.03%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Pacira Biosciences, Inc.'s return on equity of 2.81%.

Atara Biotherapeutics, Inc. has a consensus price target of $16.33, signalling upside risk potential of 15.02%. On the other hand Pacira Biosciences, Inc. has an analysts' consensus of $30.17 which suggests that it could grow by 25.8%. Given that Pacira Biosciences, Inc. has higher upside potential than Atara Biotherapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.416, which suggesting that the stock is 141.609% less volatile than S&P 500. In comparison Pacira Biosciences, Inc. has a beta of 0.233, suggesting its less volatile than the S&P 500 by 76.72%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacira Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Pacira Biosciences, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are smaller than Pacira Biosciences, Inc. quarterly revenues of $179.5M. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than Pacira Biosciences, Inc.'s net income of $5.4M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 6.48x while Pacira Biosciences, Inc.'s PE ratio is 53.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.11x versus 1.55x for Pacira Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of --. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Palatin Technologies's return on equity of --.

Atara Biotherapeutics, Inc. has a consensus price target of $16.33, signalling upside risk potential of 15.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Atara Biotherapeutics, Inc., analysts believe Palatin Technologies is more attractive than Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.416, which suggesting that the stock is 141.609% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are larger than Palatin Technologies quarterly revenues of --. Atara Biotherapeutics, Inc.'s net income of -$4.3M is higher than Palatin Technologies's net income of --. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 6.48x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.11x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.